Search | TVST | ARVO Journals

Showing 1 – 19 of 19

SORT: Best Match Most Recent Oldest

VIEW: Basic | Expanded

ARVO Annual Meeting Abstract June 2024

Oral APX3330, a Ref-1 Inhibitor, Slows Progression of Diabetic Retinopathy on a Binocular DRSS Person-Level Scale

Daniel Su; Jay Stuart Pepose; Barbara Withers; Mitchell G Brigell; Audrey Lazar; Ronil Patel; George Magrath; Peter K Kaiser; David S Boyer

Invest. Ophthalmol. Vis. Sci.. 2024; 65(7):958.

ARVO Annual Meeting Abstract June 2023

Phentolamine Ophthalmic Solution Rapidly Reverses Pharmacologically Induced Mydriasis in Two Pivotal Phase 3 MIRA Trial

Mina Sooch; Jay Stuart Pepose; Louis Haddad; Amar Khatri; Audrey Lazar; Drey Coleman; Mitchell G Brigell

Invest. Ophthalmol. Vis. Sci.. 2023; 64(8):3099.

ARVO Annual Meeting Abstract June 2023

VEGA-1 Phase 2 Trial: Phentolamine Ophthalmic Solution Maintains Pupillary Light Reflex with Improved Distance-Corrected Near Vision in Presbyopes

Ronil Patel; Mitchell G Brigell; Jay Stuart Pepose; Louis Haddad; Drey Coleman

Invest. Ophthalmol. Vis. Sci.. 2023; 64(8):2507.

ARVO Annual Meeting Abstract June 2023

Phentolamine Ophthalmic Solution, with and without Low Dose Pilocarpine, Provides Durable Improvement in Distance Corrected Near Vision in Presbyopic Patients: A Responder Analysis

Mitchell G Brigell; Jay Stuart Pepose; Kavon Rahmani; Louis Haddad; Mina Sooch

Invest. Ophthalmol. Vis. Sci.. 2023; 64(8):5423.

ARVO Annual Meeting Abstract June 2023

ZETA-1 Phase 2 Trial to Determine the Safety and Efficacy of APX3330: a Novel, Oral Ref-1 Inhibitor for the Treatment of Diabetic Retinopathy

Daniel Su; Jay Stuart Pepose; Mark R Kelley; Audrey Lazar; Louis Haddad; Mina Sooch; Mitchell G Brigell; Peter K Kaiser; David S Boyer

Invest. Ophthalmol. Vis. Sci.. 2023; 64(8):3753.

ARVO Annual Meeting Abstract June 2023

LYNX-1: A Phase 3 Randomized Placebo-Controlled Trial of Phentolamine Ophthalmic Solution in Subjects with Dim Light Vision Disturbances

Jay Stuart Pepose; Louis Haddad; Audrey Lazar; Mina Sooch; Mitchell G Brigell

Invest. Ophthalmol. Vis. Sci.. 2023; 64(8):2506.

ARVO Annual Meeting Abstract June 2022

VEGA-1: Phentolamine Ophthalmic Solution as a Single Agent Improves Distance-Corrected Near Visual Acuity in Patients with Presbyopia

James Katz; Eliot Lazar; Ajay Kolli; Ronil Patel; Kavon Rahmani; Mina Sooch; Mitchell G Brigell; Jay Stuart Pepose

Invest. Ophthalmol. Vis. Sci.. 2022; 63(7):1813 – F0429.

ARVO Annual Meeting Abstract June 2022

The Efficacy of Phentolamine Ophthalmic Solution and Low-Dose Pilocarpine to Improve Distance-Corrected Intermediate Visual Acuity in Patients with Presbyopia

Jay Stuart Pepose; Ajay Kolli; Ronil Patel; Kavon Rahmani; Mina Sooch; Mitchell G Brigell; Eliot Lazar

Invest. Ophthalmol. Vis. Sci.. 2022; 63(7):1809 – F0425.

Clinical Trials January 2022

Tie2 Activation via VE-PTP Inhibition With Razuprotafib as an Adjunct to Latanoprost in Patients With Open Angle Glaucoma or Ocular Hypertension

PDF

Mitchell Brigell; Barbara Withers; Akshay Buch; Kevin G. Peters
TAGS: intraocular pressure, latanoprost, ocular hypertension, open-angle glaucoma, conjunctival injection
Trans. Vis. Sci. Tech.. 2022; 11(1):7. https://doi.org/10.1167/tvst.11.1.7

Includes: Supplemental Content

Articles December 2021

Anti-NOGO Antibody Neuroprotection in a Rat Model of NAION

PDF

Mary A. Johnson; Zara Mehrabian; Yan Guo; Joy Ghosh; Mitchell G. Brigell; Steven L. Bernstein
TAGS: antibodies, eye, neuroprotection, nonarteritic anterior ischemic optic neuropathy, optic nerve, evoked potentials, visual, inflammation, immunohistochemistry, axon
Trans. Vis. Sci. Tech.. 2021; 10(14):12. https://doi.org/10.1167/tvst.10.14.12

Physiology and Pharmacology December 2020

A Small Molecule Inhibitor of VE-PTP Activates Tie2 in Schlemm's Canal Increasing Outflow Facility and Reducing Intraocular Pressure

PDF

Guorong Li; Astrid F. Nottebaum; Mitchell Brigell; Iris D. Navarro; Ute Ipe; Sarthak Mishra; Maria Gomez-Caraballo; Heather Schmitt; Brandi Soldo; Steve Pakola; Barbara Withers; Kevin G. Peters; Dietmar Vestweber; W. Daniel Stamer

Invest. Ophthalmol. Vis. Sci.. 2020; 61(14):12. https://doi.org/10.1167/iovs.61.14.12

Includes: Supplemental Content

Articles August 2020

Enhancing Risk Assessment in Patients with Diabetic Retinopathy by Combining Measures of Retinal Function and Structure

PDF

Mitchell G. Brigell; Bryce Chiang; April Yauguang Maa; C. Quentin Davis
TAGS: diabetic retinopathy, risk assessment, electroretinography, diabetes mellitus
Trans. Vis. Sci. Tech.. 2020; 9(9):40. https://doi.org/10.1167/tvst.9.9.40

Includes: Supplemental Content

ARVO Annual Meeting Abstract June 2020

Predictive Value of ERG, OCT-A, and UWF-FA in Patients with Diabetic Retinopathy

Mitchell G Brigell; Quentin Davis; Nadia K Waheed

Invest. Ophthalmol. Vis. Sci.. 2020; 61(7):4038.

ARVO Annual Meeting Abstract June 2020

OCTA metrics in the macula and optic nerve head predict diabetic retinopathy disease progression

Eugenia Paula Custo Greig; Mitchell G Brigell; Barbara Withers; Kevin G Peters; Eric Moult; James G Fujimoto; Nadia K Waheed

Invest. Ophthalmol. Vis. Sci.. 2020; 61(7):4039.

ARVO Annual Meeting Abstract July 2019

Enhancing Risk Assessment in Patients with Diabetic Retinopathy (DR) by Adding Retinal Function Assessment to Structural Information

Mitchell G Brigell; Bryce Chiang; April Yauguang Maa; C Quentin Davis

Invest. Ophthalmol. Vis. Sci.. 2019; 60(9):5313.

ARVO Annual Meeting Abstract July 2018

Subcutaneous Administration of AKB-9778, a Tie2 Activator, Reduces IOP in Patients with Diabetic Retinopathy

Mitchell G Brigell; Victor H Gonzalez; Darren J Bell; Arshad M. Khanani; Barbara Withers; Laura Gambino; Peter A Campochiaro; Kevin G Peters; Steve Pakola

Invest. Ophthalmol. Vis. Sci.. 2018; 59(9):1252.

ARVO Annual Meeting Abstract April 2014

A Phase 1b/2a Open-Label, Multiple-Ascending Dose Cohort Study to Assess the Safety, Tolerability, Pilot Efficacy, Pharmacokinetics and Pharmacodynamic Effects of 28-Day Repeat Subcutaneous Doses of AKB-9778 in Subjects with Diabetic Macular Edema

Mitchell G Brigell; Peter A Campochiaro; Raafay Sophie; Michael Tolentino; Daniel Miller; David Browning; David S Boyer; Jeffrey S Heier; Kevin Peters

Invest. Ophthalmol. Vis. Sci.. 2014; 55(13):1757.

ARVO Annual Meeting Abstract June 2013

IV Secukinumab Is An Effective Treatment In Patients With Noninfectious Uveitis Requiring Steroid Sparing Immunosuppressive Therapy

Erik Letko; Steven Yeh; Cynthia Grosskreutz; Uwe Pleyer; C. Stephen Foster; Mitchell Brigell

Invest. Ophthalmol. Vis. Sci.. 2013; 54(15):5929.

ARVO Annual Meeting Abstract April 2011

Twelve-Month Progression of Dark Adaptation Impairment in Patients with Early to Intermediate AMD

Gregory R. Jackson; Laura E. Walter; Ingrid U. Scott; Mark E. Clark; Mitchell G. Brigell

Invest. Ophthalmol. Vis. Sci.. 2011; 52(14):121.

NARROW

Content Type

Journal

Article Type

Topics

Tags

Specify Date Range

Oral APX3330, a Ref-1 Inhibitor, Slows Progression of Diabetic Retinopathy on a Binocular DRSS Person-Level Scale

Phentolamine Ophthalmic Solution Rapidly Reverses Pharmacologically Induced Mydriasis in Two Pivotal Phase 3 MIRA Trial

VEGA-1 Phase 2 Trial: Phentolamine Ophthalmic Solution Maintains Pupillary Light Reflex with Improved Distance-Corrected Near Vision in Presbyopes

Phentolamine Ophthalmic Solution, with and without Low Dose Pilocarpine, Provides Durable Improvement in Distance Corrected Near Vision in Presbyopic Patients: A Responder Analysis

ZETA-1 Phase 2 Trial to Determine the Safety and Efficacy of APX3330: a Novel, Oral Ref-1 Inhibitor for the Treatment of Diabetic Retinopathy

LYNX-1: A Phase 3 Randomized Placebo-Controlled Trial of Phentolamine Ophthalmic Solution in Subjects with Dim Light Vision Disturbances

VEGA-1: Phentolamine Ophthalmic Solution as a Single Agent Improves Distance-Corrected Near Visual Acuity in Patients with Presbyopia

The Efficacy of Phentolamine Ophthalmic Solution and Low-Dose Pilocarpine to Improve Distance-Corrected Intermediate Visual Acuity in Patients with Presbyopia

Tie2 Activation via VE-PTP Inhibition With Razuprotafib as an Adjunct to Latanoprost in Patients With Open Angle Glaucoma or Ocular Hypertension

Anti-NOGO Antibody Neuroprotection in a Rat Model of NAION

A Small Molecule Inhibitor of VE-PTP Activates Tie2 in Schlemm's Canal Increasing Outflow Facility and Reducing Intraocular Pressure

Enhancing Risk Assessment in Patients with Diabetic Retinopathy by Combining Measures of Retinal Function and Structure

Predictive Value of ERG, OCT-A, and UWF-FA in Patients with Diabetic Retinopathy

OCTA metrics in the macula and optic nerve head predict diabetic retinopathy disease progression

Enhancing Risk Assessment in Patients with Diabetic Retinopathy (DR) by Adding Retinal Function Assessment to Structural Information

Subcutaneous Administration of AKB-9778, a Tie2 Activator, Reduces IOP in Patients with Diabetic Retinopathy

A Phase 1b/2a Open-Label, Multiple-Ascending Dose Cohort Study to Assess the Safety, Tolerability, Pilot Efficacy, Pharmacokinetics and Pharmacodynamic Effects of 28-Day Repeat Subcutaneous Doses of AKB-9778 in Subjects with Diabetic Macular Edema

IV Secukinumab Is An Effective Treatment In Patients With Noninfectious Uveitis Requiring Steroid Sparing Immunosuppressive Therapy

Twelve-Month Progression of Dark Adaptation Impairment in Patients with Early to Intermediate AMD

To View More...

You must be signed into an individual account to use this feature.